Publikationen Prof. Dr. med. Peter J. Wild


Seoane M, Buhs S, Iglesias P, Strauss J, Puller AC, Müller J, Gerull H, Feldhaus S, Alawi M, Brandner JM, Eggert D, Du J, Thomale J, Wild PJ, Zimmermann M, Sternsdorf T, Schumacher U, Nollau P, Fisher DE, Horstmann MA (2018) Lineage-specific control of TFIIH by MITF determines transcriptional homeostasis and DNA repair. Oncogene.

IF 6.854


Keller EX, Bachofner J, Britschgi AJ, Saba K, Mortezavi A, Kaufmann B, Fankhauser CD, Wild P, Sulser T, Hermanns T, Eberli D, Poyet C (2018) Prognostic value of unifocal and multifocal positive surgical margins in a large series of robot-assisted radical prostatectomy for prostate cancer. World J. Urol.

IF 2.981


Lee DD, Leão R, Komosa M, Gallo M, Zhang CH, Lipman T, Remke M, Heidari A, Nunes NM, Apolónio JD, Price AJ, De Mello RA, Dias JS, Huntsman D, Hermanns T, Wild PJ, Vanner R, Zadeh G, Karamchandani J, Das S, Taylor MD, Hawkins CE, Wasserman JD, Figueiredo A, Hamilton RJ, Minden MD, Wani K, Diplas B, Yan H, Aldape K, Akbari MR, Danesh A, Pugh TJ, Dirks PB, Castelo-Branco P, Tabori U (2018) DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. J. Clin. Invest. 129:223-229.

IF 13.250


Leão R, Lee D, Figueiredo A, Hermanns T, Wild P, Komosa M, Lau I, Mistry M, Nunes NM, Price AJ, Zhang C, Lipman T, Poyet C, Valtcheva N, Oehl K, Coelho H, Sayyid R, Gomes AM, Prado E Castro L, Sweet J, Vinagre J, Apolónio J, Stephens D, Faleiro I, Fadaak K, Richard PO, Kulkarni G, Zlotta AR, Hamilton RJ, Castelo-Branco P, Tabori U (2018) Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer. Int. J. Cancer. 144:1676-1684.

IF 5.444


Rulle U, Tsourti Z, Casanova R, Deml KF, Verbeken E, Thunnissen E, Warth A, Cheney R, Sejda A, Speel EJ, Madsen LB, Nonaka D, Navarro A, Sansano I, Marchetti A, Finn SP, Monkhorst K, Kerr KM, Haberecker M, Wu C, Zygoura P, Kammler R, Geiger T, Gendreau S, Schulze K, Vrugt B, Wild P, Moch H, Weder W, Ciftlik AT, Dafni U, Peters S, Bubendorf L, Stahel RA, Soltermann A (2018) Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort. J. Thorac. Oncol. 13:1851-1863.

IF 10.336


Arvaniti E, Fricker K S, Moret M, Rupp N, Hermanns T, Fankhauser C, Wey N, Wild P J, Rüschoff J H, Claassen M (2018) Automated Gleason grading of prostate cancer tissue microarrays via deep learning. Sci Rep. 8:12054.

IF 4.259


Guo T, Li L, Zhong Q, Rupp N J, Charmpi K, Wong C E, Wagner U, Rueschoff J H, Jochum W, Fankhauser C D, Saba K, Poyet C, Wild P J, Aebersold R, Beyer A (2018) Multi-region proteome analysis quantifies spatial heterogeneity of prostate tissue biomarkers. Life Sci Alliance 1: e201800042.


Zhong Q, Wagner U, Kurt H, Molinari F, Cathomas G, Komminoth P, Barman-Aksözen J, Schneider-Yin X, Rey JP, Vassella E, Rogel U, Diebold J, McKee T, Jochum W, Kashofer K, Hofman P, Zischka M, Moch H, Rechsteiner M, Wild P J (2018) Multi-laboratory proficiency testing of clinical cancer genomic profiling by next-generation sequencing. Pathol. Res. Pract. 214:957-963.

IF 2.994


Brandt L P, Albers J, Hejhal T, Pfundstein S, Gonçalves A F, Catalano A, Wild P J, Frew I J (2018) Mouse genetic background influences whether HrasG12V expression plus Cdkn2a knockdown causes angiosarcoma or undifferentiated pleomorphic sarcoma. Oncotarget. 9:19753-19766.

IF 5.168


Velizheva N P, Rechsteiner M P, Valtcheva N, Freiberger S N, Wong C E, Vrugt B, Zhong Q, Wagner U, Moch H, Hillinger S, Schmitt-Opitz I, Soltermann A, Wild P J, Tischler V (2018) Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study. Pathol. Res. Pract. 214:572-578.

IF 2.994


Rechsteiner M, Dedes K, Fink D, Pestalozzi B, Sobottka B, Moch H, Wild P, Varga Z (2018) Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features. J Cancer Res Clin Oncol. 144:865-874.

IF 3.503


Morshaeuser L, May M, Burger M, Otto W, Hutterer GC, Pichler M, Klatte T, Wild P, Buser L, Brookman-May S (2018) p53-expression in patients with renal cell carcinoma correlates with a higher probability of disease progression and increased cancer-specific mortality after surgery but does not enhance the predictive accuracy of robust outcome models. Urol Oncol. 36:94.

IF 0.818


Oehl K, Kresoja-Rakic J, Opitz I, Vrugt B, Weder W, Stahel R, Wild P, Felley-Bosco E (2018) Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression. Front. Oncol. 8:40.


Erichsen L, Ghanjati F, Beermann A, Poyet C, Hermanns T, Schulz WA, Seifert H H, Wild P J, Buser L, Kröning A, Braunstein S, Anlauf M, Jankowiak S, Hassan M, Bendhack M L, Bravo M A, Santourlidis S (2018) Aberrant methylated key genes of methyl group metabolism within the molecular etiology of urothelial carcinogenesis. Sci Rep. 8:3477.

IF 4.259



Fankhauser C D, Schüffler P J, Gillessen S, Omlin A, Rupp N J, Rueschoff J H, Hermanns T, Poyet C, Sulser T, Moch H, Wild P J (2017) Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget. 9:10284-10293.

IF 5.168


Gonçalves AF, Adlesic M, Brandt S, Hejhal T, Harlander S, Sommer L, Shakhova O, Wild P J, Frew I J (2017) Evidence of renal angiomyolipoma neoplastic stem cells arising from renal epithelial cells. Nat. Commun. 8:1466.

IF 12.124


Brandt LP, Albers J, Hejhal T, Catalano A, Wild P J, Frew IJ (2017) Oncogenic HrasG12V expression plus knockdown of Cdkn2a using ecotropic lentiviral vectors induces high-grade endometrial stromal sarcoma. PLoS One. 12(10): e0186102.

IF 2.806


Singer J, Ruscheweyh H J, Hofmann AL, Thurnherr T, Singer F, Toussaint NC, Ng C K Y, Piscuoglio S, Beisel C, Christofori G, Dummer R, Hall M N, Krek W, Levesque M, Manz M G, Moch H, Papassotiropoulos A, Stekhoven DJ, Wild P, Wüst T, Rinn B, Beerenwinkel N (2017) NGS-pipe: a flexible, easily extendable, and highly configurable framework for NGS analysis. Bioinformatics (accepted).

IF 7.307


Nørgaard M, Haldrup C, Storebjerg T M, Vestergaard E M, Wild P J, Høyer S, Borre M, Ørntoft T F, Sørensen K D (2017) Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis. Int J Mol Sci. 18(9).

IF 3.226


Shved N, Warsow G, Eichinger F, Hoogewijs D, Brandt S, Wild P, Kretzler M, Cohen CD, Lindenmeyer MT (2017) Transcriptome-based network analysis reveals renal cell type-specific dysregulation of hypoxia-associated transcripts. Sci. Rep. 7:8576.

IF 4.259


Dai X, Gan W, Li X, Zhang W, Liu S, Zhong Q, Guo J, Zhang J, Chen T, Shimizu K, Beca F, Blattner M, Vasudevan D, Buckley D L, Buser L, Liu P, Inuzuka H, Beck A H, Wild P J, Theurillat J P, Garraway L A, Rubin M A, Barbieri C E, Wong K K, Huang J, Bradner J E, Wei W (2017) Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat. Medicine 23:1063-71.

IF 29.886


Janouskova H, El Tekle G, Bellini E, Udeshi N D, Rinaldi A, Ulbricht A, Bernasocchi T, Civenni G, Losa M, Svinkina T, Bielski C M, Kryukov G V, Cascione L,  Enchev R I,  Mutch D G, Carney M E, Berchuck A, Winterhoff B J N, Broaddus R R, Schraml S, Moch H, Dai X, Gan W, Wei W, Bertoni F, Catapano, Peter M, Carr S A, Garraway L A, Wild P J, Theurillat J P (2017) Cancer Type-Specific SPOP Mutants Alter BET Protein Levels and Inhibitor Responses. Nat. Medicine. 23:1046-105.

IF 29.886


Harlander S, Schönenberger D, Toussaint N C, Prummer M, Catalano A, Brandt L, Moch H, Wild P J, Frew I J (2017) Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice. Nat. Medicine. 23:869-877.

IF 29.886


Lautenbach N, Müntener M, Zanoni P, Saleh L, Saba K, Umbehr M, Velagapudi S, Hof D, Sulser T, Wild P J, von Eckardstein A, Poyet C (2017) Prevalence and causes of abnormal PSA recovery. Clin. Chem. Lab. Med. (accepted).

IF 3.432


Mortezavi A, Salemi S, Rupp NJ, Rüschoff JH, Hermanns T, Poyet C, Randazzo M, Simon HU, Moch H, Sulser T, Wild P, Eberli D (2017) Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death. Oncotarget. 8:31765-31774.

IF 5.168


Roudnicky F, Dieterich LC, Poyet C, Buser L, Wild P, Tang D, Camenzind P, Ho CH, Otto VI, Detmar M (2017) High expression of insulin receptor on tumour-associated blood vessels in invasive bladder cancer predicts poor overall and progression-free survival. J Pathol. 242:193-205.

IF 6.894


Weyerer V, Schneckenpointner R, Filbeck T, Burger M, Hofstaedter F, Wild P J, Fine S W, Humphrey P A, Dehner L P, Amin M B, Rüschoff J, Boltze C, Tannapfel A, Zwarthoff E, Lopez-Beltran A, Montironi R, Langner C, Stoehr R, Hartmann A, Giedl J (2017) Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years. J Cancer. 8:323-331.


Corrò C, Hejhal T, Poyet C, Sulser T, Hermanns T, Winder T, Prager G, Wild P J, Frew I, Moch H, Rechsteiner M (2017) Detecting circulating tumor DNA in renal cancer: An open challenge. Exp Mol Pathol. 102:255-261.

IF 2.423


Zhong W, Guo T, Rechsteiner M, Rueschoff J H, Rupp N J, Fankhauser C, Saba K, Mortezavi A, Poyet C, Hermanns T, Zhu Y, Moch H, Aebersold R, Wild P J (2017) A curated collection of tissue microarray images and clinical outcome data of prostate cancer patients. Sci. Data. 4:170014.

IF 4.836


Wettstein M S, Saba K, Umbehr M H, Murtola T J, Fankhauser C D, Adank J P, Hofmann M, Sulser T, Hermanns T, Moch H, Wild P, Poyet C (2017) Prognostic Role of Preoperative Serum Lipid Levels in Patients Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer. Prostate. 77:549-556.

IF 3.778


Valtcheva N, Winder F M, Noske A, Samartzis E P, Schmidt A M, Bellini E, Fink D, Moch H, Rechsteiner M, Dedes K J, Wild P J (2017) Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing – a case report. BMC Cancer. 17:66.

IF 3.265


Velizheva N P, Rechsteiner M P, Wong C E, Zhong Q, Rössle M, Bode B, Moch H, Soltermann A, Wild P J*, Tischler V* (2017) Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung. Cancer Cytopathol. 125:30-40.

IF 3.183




Strand S H, Switnicki M, Moller M, Haldrup C, Storebjerg T M, Hedegaard J, Nordentoft I, Hoyer S, Borre M, Pedersen J S, Wild P J, Park J Y, Orntoft T F, Sorensen K D (2016). RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.Oncotarget (accepted).

IF 6.395


Noske A, Brandt S, Valtcheva N, Wagner U, Zhong Q, Bellini E, Fink D, Obermann EC, Moch H, Wild P J (2016) Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer. Oncotarget (accepted).

IF 6.395


Zhong Q, Rüschoff J H, Guo T, Gabrani M, Schüffler P J, Rechsteiner M, Liu Y, Fuchs T J, Rupp N J, Fankhauser C, Buhmann J M, Perner S, Poyet C, Blattner M, Soldini D, Moch H, Rubin M A, Noske A, Rüschoff J, Haffner M C, Jochum W, Wild PJ (2016) Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity. Sci. Rep., 6:24146.

IF 5.578


Groner A C, Cato L, Tribolet-Hardy J, Bernasocchi T, Janouskova H, Melchers D, Houtman R, Cato A C B, Tschopp P, Gu L, Corsinotti A, Zhong Q, Fankhauser C, Fritz C, Poyet C, Wagner U, Guo T, Aebersold R, Garraway LA, Wild P J, Theurillat J P, Brown M. (2016) TRIM24 is an oncogenic transcriptional activator in prostate cancer. Cancer Cell, 29:846-58.

IF 23.523


Guinot A, Lehmann H, Wild P J, Frew I J (2016) Combined deletion of Vhl, Trp53 and Kif3a causes cystic and neoplastic renal lesions. J. Pathol., 239:365-73.

IF 7.381


Mortezavi A, Keller E X, Poyet C, Hermanns T, Saba K, Randazzo M, Fankhauser C D, Wild P J, Moch H, Sulser T, Eberli D (2016) Clinical impact of prostate biopsy undergrading in an academic and community setting. World J Urol., 34:1481-90.

IF 2.666


Haldrup C, Lynnerup AS, Storebjerg TM, Vang S, Wild P, Visakorpi T, Arsov C, Schulz WA, Lindberg J, Grönberg H, Egevad L, Borre M, Ørntoft TF, Høyer S, Sørensen KD (2016) Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels. Mol Oncol., 10: 825-37.

IF 5.331


Schönenberger D, Harlander S, Rajski M, Jacobs RA, Lundby AK, Adlesic M, Hejhal T, Wild PJ, Lundby C, Frew IJ (2016) Formation of renal cysts and tumors in Vhl/Trp53-deficient mice requires HIF-1α and HIF-2α. Cancer Res., 76:2025-36.

IF 9.329


Umbehr MH, Lüscher M, Hunziker R, Falkner F, Wild PJ, Poyet C, Seifert B, Müntener M (2016) Influence of Varying Assessment Parameters on the Diagnostic Accuracy of Magnetic Resonance Imaging in the Local Staging of Prostate Cancer. Urol Int., 96:309-14

IF 1.426



Poyet C, Hermanns T, Zhong Q, Drescher E, Eberli D, Burger M, Hofstaedter F, Hartmann A, Stöhr R, Zwarthoff EC, Sulser T, Wild PJ (2015) Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer. Oncol Lett., 10:2753-2760.

IF 1.554


Poyet C, Nieboer D, Bhindi B, Kulkarni GS, Wiederkehr C, Wettstein MS, Largo R, Wild P, Sulser T, Hermanns T (2015). Prostate cancer risk prediction using the novel versions of the ERSPC and PCPT risk calculators: Independent validation and comparison in a contemporary European cohort. BJU Int., (in press).

IF 3.533


Rupp N J, Schueffler P J, Zhong Q, Falkner F, Rechsteiner M, Rüschoff J H, Fankhauser C, Drach M, Largo R, Tremp M, Poyet C, Sulser T, Kristiansen G, Moch H, Buhmann J, Muentener M, Wild P J (2015). Oxygen supply maps for hypoxic microenvironment visualization in prostate cancer. J. Pathol. Inform., 7:3.


Wettstein MS, Buser L, Hermanns T, Roudnicky F, Eberli D, Baumeister P, Sulser T, Wild P, Poyet C (2015). CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer. Dis. Markers., 2015:785461. 

IF 1.562


Koch A, Lang S A, Wild P J, Gantner S, Mahli A, Spanier G, Berneburg M, Müller M, Bosserhoff A K, Hellerbrand C (2015). Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells. Oncotarget, 6:32748-60.

IF 6.395


Poyet C, Buser L, Roudnicky F, Detmar M, Hermanns T, Mannhard D, Höhn A, Rüschoff J, Zhong Q, Sulser T, Moch H, Wild P J (2015). Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer. J. Clin. Pathol., 68:819-24.

IF 2.915


Pällmann N, Braig M, Sievert H, Preukschas M, Hermans-Borgmeyer I, Schweizer M, Nagel CH, Neumann M, Wild P, Haralambieva E, Hagel C, Bokemeyer C, Hauber J, Balabanov S (2015). Biological Relevance and Therapeutic Potential of the Hypusine Modification System. J. Biol. Chem., 290:18343-60.

IF 4.573


Lehmann H, Vicari D, Wild P J, Frew I J (2015). Combined Deletion of Vhl and Kif3a Accelerates Renal Cyst Formation. J. Am. Soc. Nephrol., 26:2778-88.

IF 9.466


Albers J, Danzer C, Rechsteiner M, Lehmann H, Brandt L P, Hejhal T, Catalano A, Busenhart P, Gonçalves A F, Brandt S, Bode PK, Bode-Lesniewska B, Wild P J, Frew I J (2015). A versatile modular vector system for rapid combinatorial mammalian genetics. J. Clin. Invest., 125:1603-19.

IF 13.765


Sah B R, Burger I A, Schibli R, Friebe M, Dinkelborg L, Graham K, Borkowski S, Bacher-Stier C, Valencia R, Srinivasan A, Hany T F, Mu L, Wild P J, Schaefer NG (2015). Dosimetry and first clinical evaluation of the new 18F-radiolabeled bombesin analogue BAY 864367 in patients with prostate cancer. J. Nucl. Med., 56:372-8.

IF 5.563


Gaisa N T, Wilms H, Wild P J, Jakse G, Heidenreich A, Knuechel R (2015). In cystectomy specimens with bladder cancer whole organ embedding increases the detection rate of histopathological parameters, but not of those with prognostic significance. Virchows Arch., 466:423-32.

IF 2.560


Huber F, Montani M, Sulser T, Jaggi R, Wild P, Moch H, Gevensleben H, Schmid M, Wyder S, Kristiansen G (2015). Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer-what has gone wrong? A blueprint for the way forward in biomarker studies. Br. J. Cancer, 112:140-8.

IF 4.817



Church D N, Stelloo E, Nout R A, Valtcheva N, Depreeuw J, Ter Haar N, Noske A, Amant F, Tomlinson I P, Wild P J, Lambrechts D, Jürgenliemk-Schulz I M, Jobsen J J, Smit V T, Creutzberg C L, Bosse T (2014). Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer.J. Natl. Cancer Inst., 107:402.

IF 15.161


Theurillat J P, Udeshi N A, Errington W, Svinkina T, Baca SC, Wild P, Blattner M, Rubin M A, Moch H, Privé G, Carr S, Garraway L A (2014). Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science, 346:85-9.

IF 31.477


Hautmann AH, Schroeder J, Wild P, Hautmann MG, Huber E, Hoffstetter P, Fleck M, Girlich C (2014). Tumor-Induced Osteomalacia: Increased Level of FGF-23 in a Patient with a Phosphaturic Mesenchymal Tumor at the Tibia Expressing Periostin. Case Rep. Endocrinol., 2014:729387.


Meller S, Bicker A, Montani M, Ikenberg K, Rostamzadeh B, Sailer V, Wild P, Dietrich D, Uhl B, Sulser T, Moch H, Gorr TA, Stephan C, Jung K, Hankeln T, Kristiansen G (2014). Myoglobin expression in prostate cancer is correlated to androgen receptor expression and markers of tumor hypoxia. Virchows Arch., 465:419-27.

IF 2.560


Rechsteiner M, Müller R, Reineke T, Goede J, Bohnert A, Zhong Q, Manz M G, Moch H, Wild P J, Zimmermann D R, Tinguely M (2014). Modelling of a genetically diverse evolution of Systemic Mastocytosis with Chronic Myelomonocytic Leukemia (SM-CMML) by Next Generation Sequencing. Exp. Hematol. Oncol., 3:18.


Ikenberg K, Valtcheva N, Brandt S, Zhong Q, Wong C E, Noske A, Rechsteiner M, Rueschoff J H, Caduff R, Dellas A, Obermann E, Fink D, Fuchs T, Krek W, Moch H, Frew I J, Wild P J (2014). KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation. J. Pathol., 234:239-52.

IF 7.429


Kristensen H, Haldrup C, Strand S, Mundbjerg K, Mortensen M M, Thorsen K, Ostenfeld M S, Wild P J, Arsov C, Goering W, Visakorpi T, Egevad L, Lindberg J, Grönberg H, Høyer S, Borre M, Orntoft T F, Sørensen K D (2014). Hypermethylation of the GABRE~miR-452~miR-224 Promoter in Prostate Cancer Predicts Biochemical Recurrence after Radical Prostatectomy. Clin Cancer Res., 20:2169-81.

IF 7.837


Poyet C, Jentsch B, Hermanns T, Schweckendiek D, Seifert HH, Schmidtpeter M, Sulser T, Moch H, Wild P J, Kristiansen G (2014). Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. BMC Clin. Pathol., 14:10.


Valletta D, Czech B, Spruss T, Ikenberg K, Wild P, Hartmann A, Weiss T S, Oefner P J, Müller M, Bosserhoff A K, Hellerbrand C (2014). Regulation and function of the atypical cadherin FAT1 in hepatocellular carcinoma. Carcinogenesis, 35:1407-15.

IF 5.635


Giesen C, Wang H A, Schapiro D, Zivanovic N, Jacobs A, Hattendorf B, Schüffler P J, Grolimund D, Buhmann J M, Brandt S, Varga Z, Wild P J, Günther D, Bodenmiller B (2014). Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat. Methods, 11:417-22.

IF 23.231


Blattner M, Lee DJ, O'Reilly C, Park K, MacDonald T Y, Khani F, Turner K R, Chiu Y L, Wild P J, Dolgalev I, Heguy A, Sboner A, Ramazangolu S, Hieronymus H, Sawyers C, Tewari AK, Moch H, Yoon G S, Known Y C, Andrén O, Fall K, Demichelis F, Mosquera J M, Robinson B D, Barbieri C E, Rubin M A (2014). SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia 16:14-20.

IF 5.470